Skip to main content
Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
18.74
-0.15 (-0.79%)
Nov 13, 2026, 4:00 PM EST - Market closed

Denali Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
21.38--330.53108.4648.66
Revenue Growth
---204.74%122.89%-85.50%
Gross Profit
-392.2-418.78-396.44-93.35-250.27-216.69
Operating Income
-530.51-555.34-501.88-196.7-340.74-295.75
Net Income
-314.42-512.54-422.77-145.22-325.99-290.58
Earnings Per Share
-1.70-2.97-2.57-1.06-2.60-2.39
EPS Growth
------

Revenue by Segment
Chart
Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '23 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Takeda Collaboration
-1051.9229.9227.165.93
Sanofi Collaboration
-2553.4151.0720.75
Biogen Collaboration
295.79295.533.153.74307.44-
Revenue (Total)
-330.53----

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,008966.21,1921,0351,3361,291
Total Debt
35.2442.2954.3252.2460.3564.01
Net Cash (Debt)
972.33923.911,137982.271,2761,227
Net Cash Growth
17.37%-18.77%15.79%-23.01%4.00%-14.42%
Net Cash Per Share
5.275.356.927.1510.1610.10

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-444.19-412.6-347.69-357.99-244.72-211.39
Capital Expenditures
-5.81-9.5-15.91-12.94-17.83-8.5
Free Cash Flow
-449.99-422.1-363.61-370.93-262.55-219.89
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----28.24%-230.74%-
Operating Margin
-2481.12%---59.51%-314.16%-607.78%
Pretax Margin
-1470.03%---43.93%-300.54%-598.34%
Profit Margin
-1470.50%---43.94%-300.56%-597.15%
FCF Margin
-2104.54%---112.22%-242.06%-451.88%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-46.4646.4646.4646.4646.46
PS Ratio
140.48--8.9734.82111.93